Ovarian Microcystic Stromal Tumor: Report of A New Entity with Immunohistochemical and Ultrastructural Studies

Yang, Mary Y; Bhattacharjee, Meenakshi B.

doi:10.3109/01913123.2014.893045

Cited by 15 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we report six new cases of MCST, in addition to the one reported previously . Based on the current report in combination with previous publications, we conclude that ovarian MCST is a unique entity with distinct features among ovarian neoplasms. Although there is some morphological overlap with other ovarian neoplasms, the characteristic morphology of MCST comprises variable‐sized microcysts, frequent hyalinized stromal plaques and bland round‐to‐ovoid cells.…”

Section: Discussionsupporting

confidence: 80%

Microcystic stromal tumour of the ovary: frequent mutations of β‐catenin (CTNNB1) in six cases

Bai

Yang

et al. 2015

Histopathology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 80%

Microcystic stromal tumour of the ovary: frequent mutations of β‐catenin (CTNNB1) in six cases

Bai

Yang

et al. 2015

Histopathology

View full text Add to dashboard Cite

show abstract

“…None of 14 tumors harbored the FOXL2 402C > G mutation that is frequently seen in adult granulosa cell tumor. 4 …”

Section: Molecular Resultsmentioning

confidence: 99%

“…These findings further establish that the tumorigenesis of MST involves dysregulation of the Wnt/b-catenin pathway. [2][3][4]28 b-catenin has a key role in cell-cell adhesion and binds to the cytoplasmic region of E-cadherin and acatenin at adherens junctions. 28 b-catenin also plays a critical role in the transduction of Wnt signals; in the absence of Wnt signaling, b-catenin joins a destruction complex, where it undergoes CK1a and GSK-3b phosphorylation and is subsequently degraded.…”

Section: Discussionmentioning

confidence: 99%

“…1 As demonstrated in our original study, and in 4 subsequently reported cases, MSTs are uniformly positive for CD10 and vimentin. [1][2][3][4] Inhibin, calretinin, and epithelial membrane antigen are typically negative, and focal cytokeratin positivity may occasionally be observed. In 2011, Maeda et al 2 reported 2 MSTs with aberrant b-catenin nuclear accumulation and identical mutations in exon 3 of CTNNB1, implicating dysregulation of the Wnt/b-catenin pathway in the pathogenesis of this neoplasm.…”

mentioning

confidence: 99%

“…Two additional MSTs with nuclear b-catenin, including 1 with CTNNB1 mutation, have also been very recently reported. 3,4 In a follow-up to our original study, and in light of these recent data, we sought to expand the immunohistochemical and molecular genetic profile of MST, with emphasis on markers having high sensitivity and specificity for sex cord-stromal tumors. We also hoped that further data generated from study of the largest available series of MST would reinforce the most appropriate categorization, serve as a practical aid in distinction from tumors that may enter the differential diagnosis, and inform the pathogenesis of this rare ovarian neoplasm.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Microcystic Stromal Tumor

Irving

Lee

Yip

et al. 2015

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Since our first description of the microcystic stromal tumor (MST) of the ovary, a rare and distinctive neoplasm with a definitional, usually striking microcystic pattern and a CD10+/vimentin+/inhibin-/calretinin- immunophenotype, 3 examples with β-catenin nuclear localization, and CTNNB1 mutation have been reported. We undertook a detailed immunohistochemical study and molecular analysis of CTNNB1 and FOXL2 of 15 cases of MST to further characterize this neoplasm and establish its histogenesis. Diffuse nuclear staining for FOXL2, WT-1, cyclin D1, and β-catenin was present in all tumors tested, and 12/15 were positive for steroidogenic factor-1 (SF-1). Heterozygous missense point mutations in exon 3 of CTNNB1 were detected in 8 of 14 cases, resulting in amino acid changes at codons 32, 34, 35, and 37. There was no correlation between CTNNB1 exon 3 mutation status and tumor immunophenotype. All 14 cases tested showed wild-type FOXL2. Our study establishes that MST of the ovary exhibits a characteristic FOXL2/SF-1/WT-1/cyclin D1/nuclear β-catenin-positive immunohistochemical profile, which may be useful in diagnosis and in the exclusion of histologic mimics. The presence of diffuse nuclear FOXL2 and WT-1 immunostaining in all cases and SF-1 in most supports the classification of MST within the sex cord-stromal category. Aberrant nuclear β-catenin expression, detected in all MSTs, appears to be the result of stabilizing CTNNB1 mutations in 57% of cases, providing further evidence that dysregulation of the Wnt/B-catenin pathway is involved in the tumorigenesis of MST and may involve activation of β-catenin with upregulation of cyclin D1.

show abstract

Lack of mutation of DICER1 and FOXL2 genes in microcystic stromal tumor of the ovary

et al. 2016

View full text Add to dashboard Cite

Microcystic stromal tumors (MCST), first described in 2009 by Irving et al., are rare ovarian neoplasms. The entity was introduced into the 2014 WHO classification of tumors of female reproductive organs in the group of sex cord-stromal tumors, which is rather heterogeneous. We studied three cases of ovarian tumor with the characteristic morphological features and immunohistochemical marker profiles of MCST. The three tumors showed micro, and macrocystic patterns with solid areas, and were composed of small round to spindle-shaped cells, without atypia. The tumors diffusely and strongly expressed CD10, FOXL2, and nuclear β-catenin, but without immmunoreactivity for hormone receptors, calretinin, or inhibin. Genome analyses showed no somatic mutation of exon 1 of the FOXL2 gene and of exons 24 and 25 of DICER1 gene, the latter not having been reported previously. The patients are well, without evidence of tumor progression 1 to 10 years after diagnosis.The absence of FOXL2 and DICER1 gene mutation, along with strong FOXL2 immunoreactivity provides additional evidence to place MCST within pure gonadal stromal rather than sex cord ovarian tumors.

show abstract

Ovarian Microcystic Stromal Tumor: Report of A New Entity with Immunohistochemical and Ultrastructural Studies

Cited by 15 publications

References 14 publications

Microcystic stromal tumour of the ovary: frequent mutations of β‐catenin (CTNNB1) in six cases

Microcystic stromal tumour of the ovary: frequent mutations of β‐catenin (CTNNB1) in six cases

Microcystic Stromal Tumor

Lack of mutation of DICER1 and FOXL2 genes in microcystic stromal tumor of the ovary

Contact Info

Product

Resources

About